Poland· PL-100077235
Grafalon
A antithymocyte immunoglobulin (rabbit) product containing immunoglobulinum anti-t lymphocytorum ex animale ad usum humanum, registered in Poland by Neovii Biotech GmbH. The same ATC class is registered in 11 of our 19 countries.
Checked against URPL (Poland) on
Informational only — not a medical device.
Where it is registered
Antithymocyte immunoglobulin (rabbit) is registered in 11 of 19 countries.
Countries holding a registration under ATC L04AA04 (antithymocyte immunoglobulin (rabbit)), each read from that country’s own register.
- This record: Poland, from URPL (Poland)
- 6 of them publish a price we can compare per daily dose
Antithymocyte immunoglobulin (rabbit) · ATC L04AA04
11 / 19 countries
- Belgiumprice
- Canada
- Czechiaprice
- Denmark
- Finlandprice
- Ireland
- Netherlands
- Norwayprice
- Polandprice
- Switzerlandprice
- United Kingdom
The record
At a glance
URPL (Poland)- Active substance
- Immunoglobulinum anti-T lymphocytorum ex animale ad usum humanum
- Manufacturer
- Neovii Biotech GmbH
- Country
- Poland (PL)
- ATC code
- L04AA04
- ATC class
- Antithymocyte immunoglobulin (rabbit)
- Defined daily dose
- 0.1 g, P
- Reimbursed
- Not published by this register
- Source register
- URPL (Poland)
- Last checked
- September 27, 2026
Packs & prices · 4
- gtin05909990733118
- gtin05909990733125
- gtin05909990614943
- gtin05909990614950
Regulatory notes
No shortage, Orange Book or US label notes for this record.
Same class
Other records under L04AA04
Antithymocyte immunoglobulin (rabbit), as other registers publish it.
- SwitzerlandGrafalon
- SwitzerlandGrafalon
- NorwayGrafalonNeovii Biotech
- CzechiaGRAFALONNeovii Biotech GmbH, Gräfelfing
- CzechiaGRAFALONNeovii Biotech GmbH, Gräfelfing
- United KingdomGrafalon 100mg/5ml concentrate for solution for infusion vialsImported (Germany)
- BelgiumGrafalon 20 mg/mlNeovii Biotech
- NetherlandsGrafalon 20 mg/ml concentraat voor oplossing voor infusieNeovii Biotech GmbH
Sourced from a public register and reproduced with attribution. Drug Database is not affiliated with, endorsed by, or a partner of URPL (Poland). This is an informational data service and not a medical device — verify against the official source of record before any clinical decision.
For developers
The same record over the API, and the raw payload
GET /v1/drugs/d7ada4f7-2622-4ee9-a06b-1adb01da8cf6 GET /v1/drugs/d7ada4f7-2622-4ee9-a06b-1adb01da8cf6?format=fhir
Every response carries last_synced_at, so freshness is a field rather than a promise. Below is exactly what the ingestion wrote, before any presentation — the same JSON the API returns under payload.
{
"form": "Koncentrat do sporządzania roztworu do infuzji",
"source": "urpl",
"strength": "20 mg/ml",
"packaging": "05909990733118 ¦ Lz ¦ 11634\n10 fiol. 10 ml\n05909990733125 ¦ Lz ¦ 21418\n10 fiol. 5 ml\n05909990614943 ¦ Lz ¦ 34151\n1 fiol. 5 ml\n05909990614950 ¦ Lz ¦ 47013\n1 fiol. 10 ml",
"substance": "Immunoglobulina anty-T limfocytarna pochodzenia zwierzęcego stosowana u ludzi 20 mg/ml",
"common_name": "Immunoglobulinum anti-T lymphocytorum ex animale ad usum humanum",
"pl_product_id": "100077235",
"pozwolenie_nr": "07331",
"auth_procedure": "NAR",
"authorisation_validity": "Bezterminowe"
}See everything about antithymocyte immunoglobulin (rabbit).
This page is the registration. A free account adds the label text as the regulator wrote it, what it costs per daily dose across the markets that publish a price, a feed of what changes in the registers, and an assistant that answers with its sources. Interaction severity is free; mechanism and management are on the Growth plan. No card, nothing to install.